Alumis Inc. (ALMS)
NASDAQ:ALMS
US Market

Alumis Inc. (ALMS) Stock Price & Analysis

5 Followers

ALMS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$10.45 - $13.53
Previous Close$12.6
Volume135.83K
Average Volume (3M)269.86K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$133.73M
Total Debt (Recent Filing)$32.08M
Price to Earnings (P/E)
Beta-6.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume269,855
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
Price Target Upside1.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

53.78%0.00%0.21%46.01%
53.78% Insiders
0.21% Other Institutional Investors
46.01% Public Companies and
Individual Investors

ALMS FAQ

What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $10.45 and its highest was $13.53 in the past 12 months.
    What is Alumis Inc.’s market cap?
    Currently, no data Available
    When is Alumis Inc.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Alumis Inc.’s earnings last quarter?
    Currently, no data Available
    Is Alumis Inc. overvalued?
    According to Wall Street analysts Alumis Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Alumis Inc. pay dividends?
      Alumis Inc. does not currently pay dividends.
      What is Alumis Inc.’s EPS estimate?
      Alumis Inc.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Alumis Inc. have?
      Alumis Inc. has 54,069,435 shares outstanding.
        What happened to Alumis Inc.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Alumis Inc.?
        Currently, no hedge funds are holding shares in ALMS
        ---

        Company Description

        Alumis Inc.

        Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
        ---

        Best Analysts Covering ALMS

        1 Year
        Eric Schmidt FCACantor Fitzgerald
        1 Year Success Rate
        0/0 ratings generated profit
        0%
        1 Year Average Return
        0.00%
        initiated a buy rating 2 days ago
        Copying Eric Schmidt FCA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
        Popular Stocks
        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis